Misplaced Pages

Phenylephrine/ketorolac, sold under the brand name Omidria, is a combination drug used during cataract surgery or intraocular lens replacement to prevent intraoperative miosis and to reduce postoperative pain. It contains phenylephrine and ketorolac.

Phenylephrine/ketorolac was approved for medical use in the United States in May 2014, and in the European Union in July 2015.

References

1. ^ "Omidria- phenylephrine and ketorolac injection, solution, concentrate". DailyMed. 11 December 2017. Retrieved 17 April 2020.
2. ^ "Omidria EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 17 April 2020.
3. Lawuyi LE, Gurbaxani A (2015). "The clinical utility of new combination phenylephrine/ketorolac injection in cataract surgery". Clinical Ophthalmology. 9. Auckland, N.Z.: 1249–54. doi:10.2147/OPTH.S72321. PMC 4506037. PMID 26203214.
4. "Drug Approval Package: Omidria (phenylephrine and ketorolac) Injection NDA #205388". U.S. Food and Drug Administration (FDA). 9 December 2014. Retrieved 17 April 2020.

External links

• "Ketorolac mixture with phenylephrine". Drug Information Portal. U.S. National Library of Medicine.

• Medicine

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Alpha-1 adrenergic receptor agonists
• Combination drugs
• Nonsteroidal anti-inflammatory drugs
• Ophthalmology drugs
• Vasoconstrictors
• Pharmacology stubs